Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma

  title={Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma},
  author={Ryo Nakagawa and Yasushi Onishi and Akihisa Kawajiri and Koichi Onodera and Eijiro Furukawa and Sayaka Sano and Kei Saito and Satoshi Ichikawa and Tohru Fujiwara and Noriko Fukuhara and Hideo Harigae},
  journal={Annals of Hematology},
Dear Editor, Daratumumab (Dara)-containing treatments have shown promising outcomes for relapsed and refractory multiple myeloma (RRMM) [1, 2]. Dara is an antibody against CD38, which is expressed not only on myeloma cells and B cells but also on natural killer cells and activated T cells [3]. Although the necessity of prophylaxis for herpes zoster was described in previous studies of daratumumab and recent guidelines from the European Society of Clinical Microbiology and Infectious Diseases… 

Tables from this paper

Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens
CMV reactivation was observed in both NDMM and RRMM patients who had received Daracombination regimens; therefore, CMV antigenemia monitoring may be required in patients at high risk.
Hepatitis B virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy
DARA can improve the prognosis of patients with multiple myeloma, but also potentially increase the risk of HBV reactivation, and host and viral risk factors need to be identified in such patients in order to implement a more cost-effective strategy against HBv reactivation.
Evolving Role of Daratumumab: From Backbencher to Frontline Agent.
PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
The available literature data on PD-1/PD-L1 expression profile is summarized, highlighting some discrepancies and providing a rationale for the combination with anti-CD38 antibodies, in light of the immunosuppressive effect of CD38-mediated adenosine production.
Roles of CD38 in the Immune Response to Infection
This review integrates the current knowledge on the diversity of functions mediated by CD38 in the host defense to infection to suggest that CD38 might also enhance the immunosuppressive potential of regulatory leukocytes.
  • Reactions Weekly
  • 2019


Cytomegalovirus reactivation in patients with multiple myeloma
Elderly patients with MM receiving novel agents should be monitored for CMV reactivation to allow for the timely diagnosis and treatment, especially for those with extramedullary disease.
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
Among patients with relapsed or relapsed and refractory multiple myeloma, daratumumab in combination with bortezomib and dexamethasone resulted in significantly longer progression-free survival than borteonib and DexamethAsone alone and was associated with infusion-related reactions and higher rates of thrombocytopenia and neutropenia.
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
The addition of daratumumab to lenalidomide and dexamethasone significantly lengthened progression-free survival among patients with relapsed or refractory multiple myeloma.
Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma
The risk of cytomegalovirus (CMV) reactivation in multiple myeloma (MM) patients treated with bortezomib‐based induction regimens is increased following autologous stem cell transplantation (ASCT).
CD38 antibodies in multiple myeloma: back to the future.
Deep responses and prolonged progression-free survival can be achieved in relapsed/refractory MM patients when CD38 antibodies are combined with immunomodulatory agents or proteasome inhibitors, and CD38-targeting antibodies are generally well tolerated and induce partial response or better in heavily pretreated MM patients as monotherapy.
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.
Depletion of CD38(+) immunosuppressive cells, which is associated with an increase in T-helper cells, cytotoxic T cells, T-cell functional response, and TCR clonality, represents possible additional mechanisms of action for daratumumab and deserves further exploration.
Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection
Despite high seroprevalences in some populations, a substantial percentage of women of reproductive age are CMV seronegative and thus at risk of primary CMV infection during pregnancy, and future vaccine or educational campaigns to prevent primary infection in pregnant women may need to be tailored to suit the needs of different populations.
CD38 antibodies inmultiple myeloma: back to the future. Blood 131(1):13–29
  • 2018